Cement stocks rally after SC’s conditional nod to petcoke import
Cement stocks firmed up during Thursday’s afternoon trade after
reports emerged that the SC has given its conditional approval to petcoke
import. Incidentally, petcoke is used as an alternative to coal in cement
manufacturing.
Ambuja Cement (+7%), Ramco Cement (+4%), Heidelberg (+3%), ACC
(+3%), and Ultratech Cement (+2%) surged following this announcement.
Dr.Reddy's Labs launches Hervycta in India
Dr.Reddy's Labs today announced its decision to launch Hervycta
(Trastuzumab), a biosimilar of Roche's Herceptin in India. This is mainly for
the treatment of HER2-positive cancers (early breast cancer, metastatic breast
cancer, and metastatic gastric cancer).
Dr.Reddy's Hervycta is available in strengths of 150mg and 440mg
multiple dose vials. Commenting on the launch, MV Ramana, CEO- Branded Markets
(India and emerging markets), Dr.Reddy's Labs, said, "We strive every day
to do what matters most for patients. Hervycta is a step forward in our effort
to accelerate access to cancer patients in India, in the oncology biosimilar
space."
Yes Bank stock slips 4% to land among top Nifty losers
Shares of Yes Bank slipped 4% on the NSE to land among the top
Nifty losers for the day despite the lender posting a 30.5% yoy rise in profit
at Rs1, 260.36cr for the quarter ended June 2018. The bank had posted a net
profit of Rs965.52cr in the corresponding quarter last year.
Yes Bank's NII has increased 22.67% yoy to Rs2219.14cr in Q1FY19
over Rs1, 808.93cr in Q1FY18.
Gross non-performing assets (GNPA) stood at 1.31% in Q1FY19 over
1.28% in Q4FY18, whereas net NPA (NNPA) eased to 0.59% from 0.64% during the
same period.
Glenmark announces positive phase I results of biosimilar Xolair
Glenmark has announced Phase I results of biosimilar Xolair. The
studies conducted by Glenmark have shown similarity in pharmacokinetic,
pharmacodynamic, safety and immunogenicity profiles between Glenmark’s GBR 310
(proposed Xolair biosimilar) and the reference product omalizumab (brand name
Xolair).
GBR 310 is a recombinant DNA-derived monoclonal antibody which is
proposed to indicate in the treatment of allergic asthma and chronic idiopathic
urticaria (CIU).
Liberty House to finally take over Amtek Auto
Troubled auto component maker, Amtek Auto Limited (AAL) will
finally be taken over by UK-based Liberty House. The National Company Law
Tribunal (NCLT) approved Liberty’s resolution plan. As per the plan, Liberty
will pay Rs3, 225cr to financial creditors and will infuse another Rs500cr into
AAL for stabilizing the latter’s operations. Lenders to AAL will have to take a
65% haircut. Against outstanding dues of Rs12, 603cr, they will have to settle
for only Rs4, 404cr. According to a release by AAL to the stock exchanges,
liquidation value of AAL has been determined at Rs4, 119cr.
Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
Financial Advisory Company in Indore, Stock Advisory Company in Indore , Equity Tips Free Trading Tips , MCX Tips , sebi registered advisory company , Intraday stock tips , Capitalstars Video Gallery
CapitalStars Provides Free Trial To Our Client…
0 comments:
Post a Comment